Treatment outcomes of eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis
Main Article Content
Abstract
This case series study was conducted at the National Children's Hospital from June 2023 to August 2024 on 62 patients, aiming to evaluate the treatment outcomes of eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in children. A total of 51.7% of patients were monitored through clinical assessment, gastrointestinal endoscopy, and histopathology after treatment. Oral corticosteroids and proton pump inhibitors were the most commonly used medications. After 12 weeks of treatment, clinical symptoms significantly improved; however, only 37.8% of patients had normal endoscopic findings. The reduction in erythema, nodularity, and ulcers was statistically significant (p < 0.05). Additionally, 68.6% of patients experienced a more than 75% reduction in peak eosinophil count per high-power field compared to baseline. Eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis remains a challenging condition due to the lack of a standardized treatment protocol. A combination of clinical assessment, endoscopy, and histopathology is necessary to evaluate treatment effectiveness.
Article Details
Keywords
Eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis, children, endoscopy, histology, treatment outcomes
References
2. Kinoshita Y, Sanuki T. Review of Non-Eosinophilic Esophagitis-Eosinophilic Gastrointestinal Disease (Non-EoE-EGID) and a Case Series of Twenty-Eight Affected Patients. Biomolecules. 2023;13(9):1417.
3. Papadopoulou A, Amil-Dias J, Auth MKH, et al. Joint ESPGHAN/ NASPGHAN Guidelines on Childhood Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2024;78(1): 122-152.
4. Talley NJ, Shorter RG, Phillips SF, et al. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut. 1990;31(1):54.
5. Koutri E, Papadopoulou A. Eosinophilic Gastrointestinal Diseases in Childhood. Ann Nutr Metab. 2018;73(Suppl. 4):18-28.
6. Burris D, Rosenberg CE, Schwartz JT, et al. Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2750-2758.
7. Bệnh viện Nhi Trung ương. Sổ tay khoảng tham chiếu. 2021;8-30.
8. Holguín L, Gallego-Yépes C, Toro Y, et al. Epidemiological, clinical and diagnostic characterization of children with eosinophilic gastroenteropathy. A retrospective study of three high complexity health institutions. Rev Alerg Mex Tecamachalco Puebla Mex1993. 2018;65(2):148-159.
9. Robert D Pesek, Craig C Reed, Amanda B Muir, et al. Increasing Rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2014;114(6):984.
10. Alfredo J Lucendo , Beatriz Serrano-Montalbán, Ángel Arias, et al. Efficacy of Dietary Treatment for Inducing Disease Remission in Eosinophilic Gastroenteritis. J Pediatr Gastroenterol Nutr. 2015;61(1).
11. Mayu Yamamoto, Saori Nagashima, Yoshiyuki Yamada, et al. Comparison of Nonesophageal Eosinophilic Gastrointestinal Disorders with Eosinophilic Esophagitis: A Nationwide Survey. J Allergy Clin Immunol Pract. 2021;9(9).
12. Kinoshita Y, Sanuki T. Review of Non-Eosinophilic Esophagitis-Eosinophilic Gastrointestinal Disease (Non-EoE-EGID) and a Case Series of Twenty-Eight Affected Patients. Biomolecules. 2023;13(9):1417.
13. I Melamed, S J Feanny, P M Sherman, et al. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am J Med. 2001;90(3).